Convalescent plasma: new evidence for an old therapeutic tool?

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Blood transfusion = Trasfusione del sangue

• Publication date

  2016-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2450/2015.0131-15PMID 26674811PMCID PMC4781783
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Ebola: the unexpected emerging disease].

  2015cited by this paper
• Human Ebola virus infection results in substantial immune activation

  2015cited by this paper
• Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia.

  2015cited by this paper
• Large-scale convalescent blood and plasma transfusion therapy for Ebola virus disease.

  2015cited by this paper
• First Ebola treatment is approved by WHO

  2014cited by this paper
• Solvent/detergent plasma: pharmaceutical characteristics and clinical experience

  2014cited by this paper
• Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

  2014cited by this paper
• European Centre for Disease Prevention and Control.

  2014cited by this paper
• Ebola virus disease, transmission risk to laboratory personnel, and pretransfusion testing

  2014cited by this paper
• Infectious disease. Ebola vaccine: little and late.

  2014cited by this paper
• Dengue Antibody-Dependent Enhancement: Knowns and Unknowns

  2014cited by this paper
• Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus

  2014cited by this paper
• The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis

  2014cited by this paper
• Post-exposure passive immunisation for preventing measles.

  2014cited by this paper
• Ebola virus convalescent blood products: Where we are now and where we may need to go

  2014cited by this paper
• Current methods for the reduction of blood-borne pathogens: a comprehensive literature review.

  2013cited by this paper
• Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection

  2013cited by this paper
• Role of plant expression systems in antibody production for passive immunization.

  2013cited by this paper
• Adjunctive therapies and immunomodulating agents for severe influenza

  2013cited by this paper
• State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans

  2013cited by this paper
• Emerging pathogens and their implications for the blood supply and transfusion transmitted infections

  2012cited by this paper
• Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques

  2012cited by this paper
• Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies

  2012cited by this paper
• Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease

  2012cited by this paper
• A study in scarlet-convalescent plasma for severe influenza*.

  2012cited by this paper
• Crimean Congo hemorrhagic fever: requires vigilance and not panic.

  2011cited by this paper
• Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?

  2010cited by this paper
• How Innate Immune Mechanisms Contribute to Antibody-Enhanced Viral Infections

  2010cited by this paper
• Hark back: Passive immunotherapy for influenza and other serious infections

  2010cited by this paper
• An augmented passive immune therapy to treat fulminant bacterial infections.

  2010cited by this paper
• Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection

  2010cited by this paper
• Role of Dendritic Cells in Antibody-Dependent Enhancement of Dengue Virus Infection

  2008cited by this paper
• Emil Behring's Medical Culture: From Disinfection to Serotherapy

  2007cited by this paper
• Prophylactic and Therapeutic Efficacy of Human Monoclonal Antibodies against H5N1 Influenza

  2007cited by this paper
• Neutralizing Antibody Fails to Impact the Course of Ebola Virus Infection in Monkeys

  2007cited by this paper
• Treatment of Argentine hemorrhagic fever

  2007cited by this paper
• Treatment with convalescent plasma for influenza A (H5N1) infection.

  2007cited by this paper
• Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?

  2006cited by this paper
• A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable‐bag system

  2006cited by this paper
• Successful treatment of avian influenza with convalescent plasma.

  2006cited by this paper
• Convalescent whole blood, plasma and serum in the prophylaxis of measles

  2005cited by this paper
• Convalescent whole blood, plasma and serum in the prophylaxis of measles: JAMA, 12 April, 1926; 1180-1187.

  2005cited by this paper
• Treatment of severe acute respiratory syndrome with convalescent plasma.

  2003cited by this paper
• Antibody-Dependent Enhancement of Virus Infection and Disease

  2003cited by this paper
• Treatment of severe acute respiratory syndrome with convalescent plasma.

  2003cited by this paper
• Pre- and Postexposure Prophylaxis of Ebola Virus Infection in an Animal Model by Passive Transfer of a Neutralizing Human Antibody

  2002cited by this paper
• Use of Intravenous Immunoglobulins for Prophylaxis or Treatment of Infectious Diseases

  2001cited by this paper
• Passive immunity in prevention and treatment of infectious diseases.

  2000cited by this paper
• Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee.

  1999cited by this paper
• Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections.

  1999cited by this paper
• Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections.

  1999cited by this paper
• A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro

  1997cited by this paper
• Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses.

  1996cited by this paper
• Antiviral treatment of Argentine hemorrhagic fever.

  1994cited by this paper
• PARVOVIRUS B19 INFECTION IN PEDIATRIC TRANSPLANT PATIENTS

  1993cited by this paper
• Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages

  1992cited by this paper
• Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats

  1987cited by this paper
• [Treatment of Argentine hemorrhagic fever with convalescent's plasma. 4433 cases].

  1986cited by this paper
• Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization.

  1985cited by this paper
• Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma.

  1984cited by this paper
• Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome.

  1979cited by this paper
• Ebola haemorrhagic fever in Zaire, 1976.

  1978cited by this paper
• Treatment of Influenza-Pneumonia by Use of Convalescent Human Serum

  1919cited by this paper
• Ueber das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren

  1890cited by this paper

• Recent developments and future clinical prospects of polyclonal antibody therapies

  2025cites this paper
• The assessment of parameters of convalescent plasma and their impact on COVID-19 symptoms

  2025cites this paper
• Trammels Entailed in Convalescent Plasmapheresis During the COVID-19 Pandemic: Emphasizing the Anti-SARS-CoV-2 IgG Antibody Level in Repeat Voluntary Convalescent Plasma Donors

  2025cites this paper
• Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity

  2025cites this paper
• Hyperimmune Globulins in COVID-19.

  2024cites this paper
• A Brief History of Polyclonal Antibody Therapies Against Bacterial and Viral Diseases Before COVID-19.

  2024cites this paper
• Viral sepsis: diagnosis, clinical features, pathogenesis, and clinical considerations

  2024cites this paper
• Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review

  2024cites this paper
• Extensive characterization of COVID-19 convalescent plasma from Bulgarian donors

  2024cites this paper
• Passive Immunisation in the Treatment of Infectious Diseases Related to Highly Potent Bacterial Toxins

  2024cites this paper
• The role of convalescent plasma and hyperimmune immunoglobulins in the COVID-19 pandemic, including implications for future preparedness

  2024cites this paper
• Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update

  2023cites this paper
• Clinical application of SARS-CoV-2 antibody detection and monoclonal antibody therapies against COVID-19

  2023cites this paper
• Is convalescent plasma still useful as a covid treatment?

  2023cites this paper
• Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals

  2023cites this paper
• Immunomodulation Effect of Convalescent Plasma Therapy in Severe – Critical COVID-19 Patients

  2023cites this paper
• Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update

  2023cites this paper
• Trends of participants in convalescent plasma donation for COVID-19 in Japan as the pandemic evolved

  2023cites this paper
• Convalescent Plasma Therapy against COVID-19: An update on the changing facets of the ongoing Pandemic.

  2023cites this paper
• Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development

  2023cites this paper
• Efficacy of Convalescent Plasma to Treat Long-Standing COVID-19 in Patients with B-Cell Depletion

  2023cites this paper
• Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update

  2023cites this paper
• Perceptions of Saudis Toward Participating in the COVID-19 Convalescent Plasma Clinical Trial

  2023cites this paper
• Assessment of Laboratory and Clinical Data in COVID-19 Patients Treated by Convalescent Plasma

  2023cites this paper
• Tracing down the updates on Ebola virus surges: An update on anti-ebola therapeutic strategies

  2023cites this paper
• Combating Lassa Fever in West African Sub-Region: Progress, Challenges, and Future Perspectives

  2023cites this paper
• Managing blood supplies during natural disasters, humanitarian emergencies, and pandemics: lessons learned from COVID-19

  2023cites this paper
• Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review

  2023cites this paper
• Convalescent Plasma Therapy: A Treatment of Choice for COVID-19 during Current Pandemic

  2022cites this paper
• Current challenges in different approaches to control COVID-19: a comprehensive review

  2022cites this paper
• 'Convalescent Plasma'- An Effective Treatment Option to Prevent Emerging nCOVID-19- A Review.

  2022cites this paper
• Biopharmaceuticals for prevention of COVID-19: A scoping review

  2022cites this paper
• Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic

  2022cites this paper
• Convalescent plasma for coronavirus disease 2019: A boon or bane

  2022cites this paper
• Efficacy and safety of convalescent plasma versus standard care in hospitalized patients with COVID-19 from the Peruvian Social Security Health System: open-label, randomized, controlled clinical trial

  2022cites this paper
• IMPROVING THE PRIORITIZATION PROCEDURE OF PATIENTS WITH COVID-19 IN HOSPITALS BASED ON DECISION-MAKING TECHNIQUES: A SYSTEMATIC REVIEW

  2022cites this paper
• Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma

  2022cites this paper
• Plasma-Enabled Smart Nanoexosome Platform as Emerging Immunopathogenesis for Clinical Viral Infection

  2022cites this paper
• Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection

  2022cites this paper
• Potential pharmacological Therapeutics options for COVID-19: Review

  2022cites this paper
• Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus

  2022cites this paper
• Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine

  2022cites this paper
• A review of mass spectrometry‐based analyses to understand COVID‐19 convalescent plasma mechanisms of action

  2022cites this paper
• Virus Infection and Systemic Inflammation: Lessons Learnt from COVID-19 and Beyond

  2022cites this paper
• The effect of convalescent plasma on the treatment of COVID-19 patients in Ardabil, Iran

  2022cites this paper
• Understanding COVID-19 Situation in Nepal and Implications for SARS-CoV-2 Transmission and Management

  2022cites this paper
• An overview of possible solutions putting an end to the COVID-19 pandemic

  2022cites this paper
• Convalescent plasma-the experience and journey from blockbuster to incognito: A single centre experience.

  2022cites this paper
• COVID-19: The question of genetic diversity and therapeutic intervention approaches

  2022cites this paper
• SARS-CoV-2 variants inactivation of plasma units using a riboflavin and ultraviolet light-based photochemical treatment

  2022cites this paper
• Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients

  2022cites this paper
• Convalescent plasma in COVID-19: renewed focus on the timing and effectiveness of an old therapy

  2022cites this paper
• EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION International collaborative study to evaluate a 1 st WHO reference reagent for anti-human neutrophil antigen-3a (anti-HNA-3a) IgG

  2022cites this paper
• Plasma Therapy: An Effective Treatment for Infections from Microbes with Special Reference to Coronavirus Disease 2019

  2022cites this paper
• COVID-19 Treatment Options and Their Mechanism of Action up to Now: An Overview of Clinical Trials

  2022cites this paper
• Convalescent plasma – An insight into a novel treatment of covid-19 ICU patients

  2022cites this paper
• Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report

  2022cites this paper
• MERS-CoV and Its Impact in the Middle East/Arab World

  2021cites this paper
• Clinical Outcomes of Convalescent Plasma Transfusion Therapy in Moderate to Critically Ill Covid-19 Patients: A Systematic Review and Meta-Analysis

  2021cites this paper
• Convalescent Plasma—A Light at the End of the Tunnel: A Systematic Review and Meta-analysis of Randomized Controlled Trials

  2021cites this paper
• The demographic and serological characteristics of COVID-19 convalescent plasma donors: Identification of basic criteria for optimal donor selection

  2021cites this paper
• Convalescent Plasma Therapy in COVID 19 an Indian Scenario: Comprehensive Review

  2021cites this paper
• Immunotherapy in the Treatment of COVID-19

  2021cites this paper
• Plasma therapy: a passive resistance against the deadliest

  2021cites this paper
• The Therapeutic Use of Plasma from Covid-19 Convalescent Patients

  2021cites this paper
• Dynamics of SARS-CoV-2-specific antibodies among COVID19 biobank donors in Argentina

  2021cites this paper
• Characterization of Keterah orthonairovirus and evaluation of therapeutic candidates against Keterah orthonairovirus infectious disease.

  2021cites this paper
• Safety and Efficacy of Convalescent Plasma Treatment in COVID-19 Patients: Collate Trial

  2021cites this paper
• The development of human monoclonal antibodies against Zika virus

  2021cites this paper
• A comprehensive review of COVID-19 biology, diagnostics, therapeutics, and disease impacting the central nervous system

  2021cites this paper
• Therapeutic Approaches in Modulating the Inflammatory and Immunological Response in Patients With Sepsis, Acute Respiratory Distress Syndrome, and Pancreatitis: An Expert Opinion Review

  2021cites this paper
• The impact of convalescent (Immune) plasma treatment on the clinical course of COVID-19

  2021cites this paper
• Passive immunization in the combat against infectious diseases (COVID-19 included)

  2021cites this paper
• A Step Toward Optimizing Regenerative Medicine Principle to Combat COVID-19

  2021cites this paper
• Immunological Approaches to the Treatment of New Coronavirus Infection (Review)

  2021cites this paper
• The Convalescent Plasma Craze! Where Does India Stand?

  2021cites this paper
• The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections

  2021cites this paper
• An Update on Transfusion Related Immunomodulation (TRIM) in a Time of COVID- 19 Pandemic

  2021cites this paper
• Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application

  2021influential citation
• Should timing be considered before abandoning convalescent plasma in covid-19? Results from the Turkish experience

  2021cites this paper
• Preservation of anti-SARS-CoV-2 neutralising antibodies in convalescent plasma after pathogen reduction with methylene blue and visible light.

  2021cites this paper
• Efficacy of Convalescent Plasma Therapy in Hospitalized COVID- 19 Patients: A Single Center Retrospective Analysis of 190 Cases in Lebanon

  2021cites this paper
• Hyperinflammation Syndrome in COVID-19 Disease: Pathogenesis and Potential Immunomodulatory Agents

  2021cites this paper
• Convalescent Plasma Reduces Endogenous Antibody Response in COVID-19: A Retrospective Cross-Sectional Study

  2021cites this paper
• Successful treatment of COVID‐19 infection with convalescent plasma in B‐cell‐depleted patients may promote cellular immunity

  2021cites this paper
• Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review

  2021cites this paper
• Convalescent Plasma Therapy in SARS-COV-2 Infection, Experience in Tucumán Argentina: An Observational Study

  2021influential citation
• Date of publication xxxx 00, 0000, date of current version xxxx 00, 0000

  2021cites this paper
• Coronavirus Disease 2019: Prevention and Safety in the Dental Office

  2021cites this paper
• Statins in COVID-19 Therapy

  2021cites this paper
• Are mesenchymal stem cells able to manage cytokine storm in COVID-19 patients? A review of recent studies

  2021cites this paper
• How we secured a COVID‐19 convalescent plasma procurement scheme in Japan

  2021cites this paper
• Use of Convalescent Plasma Therapy for COVID-19: A Scientometric Assessment of Global Publications during 2020-21

  2021influential citation
• Promising Immunotherapies against COVID‐19

  2021cites this paper
• COVID-19 convalescent plasma: mechanisms of action and rationale for use: a narrative review

  2021cites this paper
• Convalescent Plasma Immunotherapy - A Possible Mitigation Strategy for SARS-CoV-2 Pandemic

  2021cites this paper
• What we learned in the past year in managing our COVID-19 patients in intensive care units?

  2021cites this paper
• RISE AND FALL IN SARS-COV-2 GLOBAL PANDEMIC STRAIN RATE–AN OVERVIEW

  2021cites this paper
• Convalescent Plasma Reduces Antibodies in COVID-19

  2021cites this paper
• SARS-CoV-2 and Plasma Hypercoagulability

  2021cites this paper